Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05413044 · ClinicalTrials.gov registry record
A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 140,706
- Enrollment target
NCT05413044: Completed study, sponsored by Bristol-Myers Squibb.
NCT05413044 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 140,706 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05413044 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 140,706 participants
- Enrollment target
Study Summary
The purpose of this study is to collect real-world data in order to estimate the frequency of overall malignancies, melanoma, basal cell carcinoma, and squamous cell carcinoma in participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) enrolled in the SRQ Register in Sweden.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140,706 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2025-10-31 |
What the finished NCT05413044 record still lists
NCT05413044 is an observational study that tracks outcomes without assigning an intervention. Its 140,706 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05413044 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05413044 about?
NCT05413044 is a clinical study titled "A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register". The purpose of this study is to collect real-world data in order to estimate the frequency of overall malignancies, melanoma, basal cell carcinoma, and squamous cell carcinoma in participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) enrolled in the SRQ Register in Sweden.
What is the current status of trial NCT05413044?
This trial is currently completed. The enrollment target is 140,706 participants. The study started on 2019-07-01. Estimated completion is 2025-10-31.
Who is sponsoring clinical trial NCT05413044?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05994482 · 130,000 participants
Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
- NCT02693509 · 128,026 participants
Get With The Guidelines-Heart Failure Registry
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI